For a safer tomorrow
Immunethep is a biotech company(spin-off from the University of Porto) that is developing high-coverage antibacterial immunotherapies based on the discovery of a new mechanism used by different pathogens to suppress the host’s immune response. PNV, the first product developed is ready to enter clinical trials, is a vaccine that simultaneously addresses 5 of the most critical bacteria for humans, responsible for 80% of bacterial infections. These bacteria are not only the cause of potentially lethal infections, but are also some of the most relevant bacteria for the increase of Antimicrobial Antibiotic Resistance (AMR). If the current progression of AMR continues, it will predictably be the world’s leading cause of death by 2050 with 10 million deaths per year. Immunethep has been building on its PIT-ID technology platform, the Platform for Immunomodulatory Therapies for Infectious Diseases, to create more products, such as a therapeutic solution for bacterial infections with monoclonal antibodies, UNImAb. Since 2020, the company has decided to contribute to the global effort to combat COVID- 19 and has applied its expertise to develop a vaccine, SILBA, that is designed to be effective against different variants of the virus and have a simple (needle-free) mode of administration. Immunethep was founded in 2013, has a team of 11 highly qualified professionals and is located in Biocant Park in Cantanhede.
